Joan Allman, DO
Internal Medicine · Parkersburg, WVNPI 1457313850
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.3% of the total across 292 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,082 and has fallen 96.1% since, to $81 in 2025. Among internal medicine clinicians in WV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 292 payments — averaging $17.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$845
- Misonix Inc$578
- Novo Nordisk$421
- Organogenesis Inc.$408
- AstraZeneca$344
- Amgen$310
- plus $2K from 26 others
What the payments were for
- Consulting fees$1002%
- Speaking & faculty fees$802%
- Food & beverage$4,82996%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 58 | $845 |
| Misonix Inc | 21 | $578 |
| Novo Nordisk | 25 | $421 |
| Organogenesis Inc. | 34 | $408 |
| AstraZeneca | 14 | $344 |
| Amgen | 27 | $310 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $272 |
| Sanofi-aventis U.S. LLC | 9 | $184 |
| Merck | 16 | $181 |
| Pfizer | 10 | $162 |
| Melinta Therapeutics, LLC | 9 | $156 |
| Bioventus LLC | 5 | $144 |
| Biohaven Pharmaceuticals, Inc. | 5 | $141 |
| Johnson & Johnson | 9 | $133 |
| Smith+Nephew | 7 | $123 |
| Comsort, Inc | 1 | $100 |
| Lilly USA, LLC | 6 | $85 |
| Amarin Pharma, Inc. | 4 | $82 |
| Teva Pharmaceuticals USA, Inc. | 4 | $52 |
| Boehringer Ingelheim | 3 | $37 |
| CSL Behring | 3 | $37 |
| Abbott | 2 | $36 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $33 |
| GSK | 2 | $31 |
| Radius Health, Inc. | 1 | $18 |
| Pharming Healthcare, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Osiris Therapeutics Inc. | 1 | $15 |
| Sunovion Pharmaceuticals Inc. | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
| Paratek Pharmaceuticals, Inc. | 1 | $13 |
| Phadia US Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$224
- NURTEC ODT$125
- BREZTRI$121
- Wegovy$104
- SIVEXTRO$100
How this compares
$5,014 in reported general payments places this provider in the 90th percentile of 573 internal medicine providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 86 | $142,348 |
| JardianceEmpagliflozin | 80 | $115,423 |
| OzempicSemaglutide | 72 | $88,201 |
| TrulicityDulaglutide | 52 | $85,954 |
| EliquisApixaban | 73 | $70,177 |
| XareltoRivaroxaban | 26 | $30,149 |
| JanuviaSitagliptin Phosphate | 22 | $28,264 |
| FarxigaDapagliflozin Propanediol | 14 | $21,248 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $18,021 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $16,783 |
| LinzessLinaclotide | 16 | $15,857 |
| RybelsusSemaglutide | 12 | $13,043 |
| MyrbetriqMirabegron | 14 | $8,120 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $5,980 |
| Repatha SyringeEvolocumab | 13 | $5,507 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $85 | $228,302138 claims |
| Boehringer IngelheimJardiance | $37 | $115,42380 claims |
| Novo NordiskOzempic, Rybelsus | $421 | $101,24484 claims |
| PfizerEliquis, Dilantin | $162 | $71,94085 claims |
| AstraZenecaFarxiga, Symbicort, Brilinta | $344 | $32,42039 claims |
| Johnson & JohnsonXarelto | $133 | $30,14926 claims |
| MerckJanuvia | $181 | $28,26422 claims |
| GSKTrelegy Ellipta | $31 | $16,78317 claims |
| AbbVieLinzess | $845 | $15,85716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 573 internal medicine providers in West Virginia.
Other internal medicine in Parkersburg
- David PickeringParkersburg$599K
- Orton ArmstrongParkersburg$9K
- Jennifer LeavittParkersburg$8K
- William TomlinsonParkersburg$7K
- William ChapmanCharleston$1.7M
- Govind PatelFairmont$59K
- Bisher MustafaHuntington$28K
- Johny AlencherryMartinsburg$27K
- Ali KhanBuckhannon$21K
- Joseph HashemBerkeley Springs$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.